Article
Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.
Oncogene - 1 Oct 2022
Harrod Alison, Lai Chun-Fui, Goldsbrough Isabella, Simmons Georgia M, Oppermans Natasha, Santos Daniela B, Győrffy Balazs, Allsopp Rebecca C, Toghill Bradley J, Balachandran Kirsty, Lawson Mandy, Morrow Christopher J, Surakala Manasa, Carnevalli Larissa S, Zhang Pei, Guttery David S, Shaw Jacqueline A, Coombes R Charles, Buluwela Lakjaya, Ali Simak
Abstract excerpt
Mutations in the estrogen receptor (ESR1) gene are common in ER-positive breast cancer patients who progress on endocrine therapies. Most mutations localise to just three residues at, or near, the C-terminal helix 12 of the hormone binding domain, at leucine-536, tyrosine-537 and aspartate-538. To investigate these mutations, we have used CRISPR-Cas9 mediated genome engineering to generate a comprehensive set of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
